@article {Fischer235, author = {Aryeh Fischer and Amanda M. Kong and Jeffrey J. Swigris and Ashley L. Cole and Karina Raimundo}, title = {All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement}, volume = {45}, number = {2}, pages = {235--241}, year = {2018}, doi = {10.3899/jrheum.170307}, publisher = {The Journal of Rheumatology}, abstract = {Objective. Patients with systemic sclerosis (SSc) often develop interstitial lung disease (ILD) and/or pulmonary arterial hypertension (PAH). The effect of ILD and PAH on healthcare costs among patients with SSc is not well described. The objective of this analysis was to describe healthcare costs in patients with newly diagnosed SSc and SSc patients newly diagnosed with ILD and/or PAH in the United States.Methods. This retrospective cohort analysis was conducted in the Truven Health MarketScan Commercial and Medicare Supplemental healthcare claims databases from 2003 to 2014. Based on International Classification of Diseases-9-Clinical Modification diagnosis codes on medical claims, patients were classified into 3 groups: incident SSc, SSc with incident ILD (SSc-ILD), and SSc with incident PAH (SSc-PAH). Patients were required to have continuous enrollment for 5 years to measure all-cause healthcare costs. Costs (adjusted to US$) were reported overall and by service type and year following diagnosis. Because of the overlap between groups, statistical comparisons were not conducted.Results. There were 1957 patients with incident SSc, 219 with incident SSc-ILD, and 108 patients with incident SSc-PAH. Average (mean {\textpm} SD) all-cause healthcare costs over followup were higher for patients with incident SSc-ILD ($191,107 {\textpm} $322,193) or patients with incident SSc-PAH ($254,425 {\textpm} $240,497), compared to patients with incident SSc ($101,839 {\textpm} $167,155). Average annual costs over the 5-year period ranged from $18,513 to $23,268 for patients with incident SSc, from $31,285 to $55,446 for patients with incident SSc-ILD, and from $44,454 to $63,320 for patients with incident SSc-PAH. Costs tended to be the highest in the fifth year of followup.Conclusion. Among patients with SSc, ILD and PAH can result in substantial increases in healthcare costs.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/45/2/235}, eprint = {https://www.jrheum.org/content/45/2/235.full.pdf}, journal = {The Journal of Rheumatology} }